Investigational Drug Information for PSN-632,408
✉ Email this page to a colleague
What is the development status for investigational drug PSN-632,408?
PSN-632,408 is an investigational drug.
There have been 7 clinical trials for PSN-632,408.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2020.
The most common disease conditions in clinical trials are Colorectal Neoplasms, Neurotoxicity Syndromes, and Infection. The leading clinical trial sponsors are Sanofi, National Cheng-Kung University Hospital, and University of Pisa.
There are sixty-four US patents protecting this investigational drug and seven hundred and thirty-seven international patents.
Summary for PSN-632,408
| US Patents | 64 |
| International Patents | 737 |
| US Patent Applications | 113 |
| WIPO Patent Applications | 62 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 3 (2020-07-01) |
| Vendors | 31 |
Recent Clinical Trials for PSN-632,408
| Title | Sponsor | Phase |
|---|---|---|
| Topical Vancomycin Over Sternal Edge in Cardiac Surgery | National Cheng-Kung University Hospital | Phase 4 |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Alberta | N/A |
| Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study | University of Toronto | N/A |
Clinical Trial Summary for PSN-632,408
Top disease conditions for PSN-632,408
Top clinical trial sponsors for PSN-632,408
US Patents for PSN-632,408
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PSN-632,408 | See Plans and Pricing | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | See Plans and Pricing |
| PSN-632,408 | See Plans and Pricing | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | See Plans and Pricing |
| PSN-632,408 | See Plans and Pricing | Substituted piperidines having GPR119 agonistic activity | DONG-A ST CO., LTD. (KR) | See Plans and Pricing |
| PSN-632,408 | See Plans and Pricing | Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent | The University of Queensland (Queensland, AU) | See Plans and Pricing |
| PSN-632,408 | See Plans and Pricing | Phenothiazin derivatives, method for the production thereof and use thereof as pharmaceuticals | Sanofi-Aventis (Paris, FR) | See Plans and Pricing |
| PSN-632,408 | See Plans and Pricing | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use | Sanofi-Aventis (Paris, FR) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PSN-632,408
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PSN-632,408 | Argentina | AR091089 | 2031-01-07 | See Plans and Pricing |
| PSN-632,408 | Argentina | AR091739 | 2031-01-07 | See Plans and Pricing |
| PSN-632,408 | Australia | AU2011317140 | 2030-10-19 | See Plans and Pricing |
| PSN-632,408 | Australia | AU2011317143 | 2030-10-19 | See Plans and Pricing |
| PSN-632,408 | Australia | AU2012204162 | 2030-10-19 | See Plans and Pricing |
| PSN-632,408 | Australia | AU2012363873 | 2030-10-19 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
